Cindy A. Leissinger, MD received her medical degree from Tulane University School of Medicine in New Orleans, Louisiana. She completed a residency in internal medicine at Tulane, a research fellowship in hematology at The National Institutes of Health in Bethesda, Maryland, and a clinical fellowship in hematology and medical oncology at Tulane.
Dr. Leissinger is currently Professor of Medicine, and Clinical Professor of Pediatrics and Pathology at Tulane University. She serves as Chief of the Hematology/Oncology Division. She is also Director of the Louisiana Center for Bleeding and Clotting Disorders. She is a fellow of the American College of Physicians and a member of the American Society of Hematology and the International Society on Thrombosis and Haemostasis. Dr. Leissinger has been a member of the Hemophilia and Thrombosis Research Society since its inception and has served the society in numerous leadership positions.
In addition to caring for patients with coagulation disorders, Dr. Leissinger oversees an active research program that receives funding from the National Institutes of Health as well as numerous other federal and industry sources. She participates in several clinical research groups, and has been an active investigator for many research studies related to bleeding disorders, with a particular interest in Factor VIII inhibitor development and management. Currently, Dr. Leissinger serves as the principal investigator for two investigator-initiated, multi-institutional clinical trials. The RICH (Rituximab for Inhibitors in Congenital Hemophilia) Study is an open NIH sponsored clinical trial designed to study the effects of rituximab on the eradication of high titer Factor VIII inhibitors. A second clinical trial, the ProFEIBA Study is an international randomized crossover study of FEIBA as secondary prophylaxis for the prevention of bleeds in hemophilia patients with inhibitors. Enrollment and active follow-up for the ProFEIBA study was recently completed and data analysis is ongoing.
Under Dr. Leissinger's direction, Tulane serves as one of 16 member institutions in the NHLBI's Transfusion Medicine/Hemostasis Clinical Trials Network. Several seminal trials developed through this network include platelet transfusion studies, as well as studies of optimal therapy in low incidence hematologic disorders such as ITP and
To view Dr. Leissinger's publications, visit PubMed.